Current and Emerging Directions in the Frontline Treatment of Follicular Lymphoma: Implications for Practice
Please use the box in the top-right corner of the screen to login or register.
Release Date: October 19, 2022
Expiration Date: October 19, 2023
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, Dr. Salles will address current and emerging directions in the frontline treatment of follicular lymphoma, he will also discuss recent evidence on emerging therapies and describe implications for current and future practice. To conclude, Dr. Armitage and Dr. Salles examine how to apply these therapies to practice and how to individualize therapy for patients.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with follicular lymphoma.
Upon completion of this educational activity, participants should be able to:
- Discuss recent evidence/publications on emerging therapies for frontline FL treatment
- Describe implications for current/future practice of new clinical trial data in the frontline treatment of FL
Current and Emerging Directions in the Frontline Treatment of FL: Implications for Practice – James O. Armitage, MD and Gilles Salles, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through October 19, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
James O. Armitage, MD
Joe Shapiro Professor of Medicine
University of Nebraska Medical Center
Dr. James Armitage received his medical degree from the University of Nebraska Medical Center, where he also completed his internship and residency in internal medicine. In addition, he completed a fellowship in hematology/oncology at the University of Iowa. Dr. Armitage is the Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center where he developed the Bone Marrow Transplant program and the Nebraska Lymphoma Study Group. He has also served as Vice Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine.
Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, and is a fellow of the American and the Royal College of Physicians, ASCO, the American Association for the Advancement of Science, and American Society for Transplantation and Cellular Therapy (ASTCT). He has served on many national/international oncology committees, including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. Dr. Armitage has published more than 600 papers, written 115 chapters, and is editor/co-editor of 33 books. He currently edits the ASCO Post and has received numerous honors.
Gilles Salles, MD, PhD
Steven Greenberg Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Gilles Salles received his medical training and obtained his doctoral degree in differentiation, genetics, and immunology at the Université Claude Bernard Lyon-1. He completed his residency in medicine at Lyon University Hospitals in Lyon, France. He completed a postdoctoral fellowship in immunology at Harvard Medical School (Dana-Farber Cancer Institute) in Boston, Massachusetts. Dr. Salles is Chief of the Lymphoma Service at the Memorial Sloan Kettering Cancer Center in New York. He has previously held a position of Professor of Hematology and Medicine at the University of Lyon, and Head of the Department of Hematology at the Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France.
During his career, Dr. Salles has been especially interested in the clinical and biological study of lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent lymphomas. He has been involved in the investigation and development of new therapeutic agents, such as several targeted therapies, new monoclonal antibodies and other immunotherapies in the field. He led large international studies evaluating treatment options in patients with follicular lymphoma.
Previously, Dr. Salles chaired the Lymphoma Study Association, a European cooperative group. He is also a member of several international societies, including the American Society of Hematology and the American Society of Clinical Oncology. He has authored more than 500 publications, including articles in international peer-reviewed journals such as The New England Journal of Medicine, Blood, Journal of Clinical Oncology, The Lancet, Haematologica, Lancet Oncology, and Leukemia and Lymphoma.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-016-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. James Armitage has relevant financial relationships related to advisory activities from Cardiff Oncology, Inc.
Dr. Gilles Salles has relevant financial relationships related to consulting from AbbVie Inc., BeiGene, Bristol Myers Squibb Company, Celgene Corporation ‒ A Bristol Myers Squibb Company, Debiopharm Group, Epizyme, Inc., Genentech - A Member of the Roche Group, Genmab A/S, Incyte Corporation, Ipsen, Janssen Pharmaceuticals, Inc., Kite Pharma/Gilead Sciences, Inc., Loxo Oncology, Miltenyi Biotec, Molecular Partners, MorphoSys AG, Nordic Nanovector ASA, Novartis AG, RAPT Therapeutics, Takeda Pharmaceuticals U.S.A., Inc., and VelosBio, Inc. He has received honoraria from AbbVie, Bayer AG, Incyte, Kite/Gilead, MorphoSys, Novartis, and Regeneron Pharmaceuticals, Inc. He is a stock shareholder of Owkin.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.